212 related articles for article (PubMed ID: 35016513)
1. What is the best treatment recommendation for HER2+ IBC with residual disease?-a narrative review.
Zakon DB; Valero V
Chin Clin Oncol; 2021 Dec; 10(6):59. PubMed ID: 35016513
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Value of HER2 to CEP17 Ratio on Fluorescence In Situ Hybridization Ratio in Patients with Nonmetastatic HER2-Positive Inflammatory and Noninflammatory Breast Cancer Treated with Neoadjuvant Chemotherapy with or without Trastuzumab.
Kogawa T; Fujii T; Wu J; Harano K; Fouad TM; Liu DD; Shen Y; Masuda H; Krishnamurthy S; Chavez-MacGregor M; Lim B; Murthy RK; Valero V; Tripathy D; Ueno NT
Oncologist; 2020 Jun; 25(6):e909-e919. PubMed ID: 32003919
[TBL] [Abstract][Full Text] [Related]
4. A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study).
Patel TA; Ensor JE; Creamer SL; Boone T; Rodriguez AA; Niravath PA; Darcourt JG; Meisel JL; Li X; Zhao J; Kuhn JG; Rosato RR; Qian W; Belcheva A; Schwartz MR; Kaklamani VG; Chang JC
Breast Cancer Res; 2019 Sep; 21(1):100. PubMed ID: 31477168
[TBL] [Abstract][Full Text] [Related]
5. Individualizing Curative-Intent Therapy in HER2-Positive Early-Stage Breast Cancer.
Martínez-Sáez O; Waks AG
Curr Treat Options Oncol; 2023 May; 24(5):479-495. PubMed ID: 36995527
[TBL] [Abstract][Full Text] [Related]
6. De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial.
Nitz U; Gluz O; Graeser M; Christgen M; Kuemmel S; Grischke EM; Braun M; Augustin D; Potenberg J; Krauss K; Schumacher C; Forstbauer H; Reimer T; Stefek A; Fischer HH; Pelz E; Zu Eulenburg C; Kates R; Wuerstlein R; Kreipe HH; Harbeck N;
Lancet Oncol; 2022 May; 23(5):625-635. PubMed ID: 35405088
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of HER2 inhibitors in combination with or without pertuzumab for HER2-positive breast cancer: a systematic review and meta-analysis.
Chen S; Liang Y; Feng Z; Wang M
BMC Cancer; 2019 Oct; 19(1):973. PubMed ID: 31638935
[TBL] [Abstract][Full Text] [Related]
8. Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer.
Denkert C; Lambertini C; Fasching PA; Pogue-Geile KL; Mano MS; Untch M; Wolmark N; Huang CS; Loibl S; Mamounas EP; Geyer CE; Lucas PC; Boulet T; Song C; Lewis GD; Nowicka M; de Haas S; Basik M
Clin Cancer Res; 2023 Apr; 29(8):1569-1581. PubMed ID: 36730339
[TBL] [Abstract][Full Text] [Related]
9. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes.
Masuda H; Brewer TM; Liu DD; Iwamoto T; Shen Y; Hsu L; Willey JS; Gonzalez-Angulo AM; Chavez-MacGregor M; Fouad TM; Woodward WA; Reuben JM; Valero V; Alvarez RH; Hortobagyi GN; Ueno NT
Ann Oncol; 2014 Feb; 25(2):384-91. PubMed ID: 24351399
[TBL] [Abstract][Full Text] [Related]
10. Patient-reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2-positive breast cancer.
Conte P; Schneeweiss A; Loibl S; Mamounas EP; von Minckwitz G; Mano MS; Untch M; Huang CS; Wolmark N; Rastogi P; D'Hondt V; Redondo A; Stamatovic L; Bonnefoi H; Castro-Salguero H; Fischer HH; Wahl T; Song C; Boulet T; Trask P; Geyer CE
Cancer; 2020 Jul; 126(13):3132-3139. PubMed ID: 32286687
[TBL] [Abstract][Full Text] [Related]
11. When to Add Additional Anti-HER2 Therapy to Adjuvant Trastuzumab.
Zimmer AS; Denduluri N
Curr Oncol Rep; 2019 Nov; 21(12):109. PubMed ID: 31781874
[TBL] [Abstract][Full Text] [Related]
12. Trastuzumab emtansine (T-DM1) versus trastuzumab in Chinese patients with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy for HER2-positive breast cancer in the phase 3 KATHERINE study.
Huang CS; Yang Y; Kwong A; Chen SC; Tseng LM; Liu MC; Shen K; Wang S; Ng TY; Feng Y; Sun G; Yan IR; Shao Z
Breast Cancer Res Treat; 2021 Jun; 187(3):759-768. PubMed ID: 33860389
[TBL] [Abstract][Full Text] [Related]
13. [Systemic treatments of inflammatory breast cancer: an overview].
Monneur A; Bertucci F; Viens P; Gonçalves A
Bull Cancer; 2014 Dec; 101(12):1080-8. PubMed ID: 25475708
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE.
Mamounas EP; Untch M; Mano MS; Huang CS; Geyer CE; von Minckwitz G; Wolmark N; Pivot X; Kuemmel S; DiGiovanna MP; Kaufman B; Kunz G; Conlin AK; Alcedo JC; Kuehn T; Wapnir I; Fontana A; Hackmann J; Polikoff J; Saghatchian M; Brufsky A; Yang Y; Zimovjanova M; Boulet T; Liu H; Tesarowski D; Lam LH; Song C; Smitt M; Loibl S
Ann Oncol; 2021 Aug; 32(8):1005-1014. PubMed ID: 33932503
[TBL] [Abstract][Full Text] [Related]
15. The Impact of Residual Disease After Preoperative Systemic Therapy on Clinical Outcomes in Patients with Inflammatory Breast Cancer.
Nakhlis F; Regan MM; Warren LE; Bellon JR; Hirshfield-Bartek J; Duggan MM; Dominici LS; Golshan M; Jacene HA; Yeh ED; Mullaney EE; Overmoyer B
Ann Surg Oncol; 2017 Sep; 24(9):2563-2569. PubMed ID: 28560598
[TBL] [Abstract][Full Text] [Related]
16. Axillary response according to neoadjuvant single or dual human epidermal growth factor receptor 2 (HER2) blockade in clinically node-positive, HER2-positive breast cancer.
Cha C; Ahn SG; Kim D; Lee J; Park S; Bae SJ; Kim JY; Park HS; Park S; Kim SI; Park BW; Jeong J
Int J Cancer; 2021 Oct; 149(8):1585-1592. PubMed ID: 34213778
[TBL] [Abstract][Full Text] [Related]
17. T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational Study.
Conte B; Fabi A; Poggio F; Blondeaux E; Dellepiane C; D'Alonzo A; Buono G; Arpino G; Magri V; Naso G; Presti D; Mura S; Fontana A; Cognetti F; Molinelli C; Pastorino S; Bighin C; Miglietta L; Boccardo F; Lambertini M; Del Mastro L;
Clin Breast Cancer; 2020 Apr; 20(2):e181-e187. PubMed ID: 31735691
[TBL] [Abstract][Full Text] [Related]
18. Dual HER2 Blockade in Neoadjuvant Treatment of HER2+ Breast Cancer: A Meta-Analysis and Review.
Wang C; Chen J; Xu X; Hu X; Kong D; Liang G; Wang X
Technol Cancer Res Treat; 2020; 19():1533033820960721. PubMed ID: 32990165
[TBL] [Abstract][Full Text] [Related]
19. Systemic treatment of patients with early breast cancer: recent updates and state of the art.
Caparica R; Brandão M; Piccart M
Breast; 2019 Nov; 48 Suppl 1():S7-S20. PubMed ID: 31839166
[TBL] [Abstract][Full Text] [Related]
20. NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2.
Fehrenbacher L; Cecchini RS; Geyer CE; Rastogi P; Costantino JP; Atkins JN; Crown JP; Polikoff J; Boileau JF; Provencher L; Stokoe C; Moore TD; Robidoux A; Flynn PJ; Borges VF; Albain KS; Swain SM; Paik S; Mamounas EP; Wolmark N
J Clin Oncol; 2020 Feb; 38(5):444-453. PubMed ID: 31821109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
